NCT02201030

Brief Summary

This study will assess the immunogenicity and safety of primary vaccination with NBP606 compared to the existing commercial vaccine, when given concomitantly with routine pediatric vaccinations.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
577

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Sep 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 16, 2014

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 25, 2014

Completed
1 month until next milestone

Study Start

First participant enrolled

September 6, 2014

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 21, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 21, 2016

Completed
Last Updated

April 20, 2020

Status Verified

October 1, 2016

Enrollment Period

2.1 years

First QC Date

July 16, 2014

Last Update Submit

April 17, 2020

Conditions

Pneumococcal Infections

Outcome Measures

Primary Outcomes (1)

  • Proportion of subjects with the targeted antibody concentration

    1 month after the primary vaccination

Secondary Outcomes (1)

  • Geometric mean concentration ratio

    1 month after the primary vaccination

Study Arms (2)

NBP606

EXPERIMENTAL

13-valent pneumococcal conjugate vaccine

Biological: NBP606

Prevnar13

ACTIVE COMPARATOR

13-valent pneumococcal conjugate vaccine

Biological: Prevnar13

Interventions

NBP606BIOLOGICAL

A single intramuscular injection into the thigh

NBP606
Prevnar13BIOLOGICAL

A single intramuscular injection into the thigh

Prevnar13

Eligibility Criteria

Age42 Days - 98 Days
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Healthy Infants between 42 and 98 days of age (approximately 2 months) at the time of enrollment.
  • The LAR (Legally Authorized Representative) who understand the requirements of the study and voluntarily consent to participate in the study.

You may not qualify if:

  • Known hypersensitivity to any components of the pneumococcal vaccine
  • Any confirmed or suspected immunosuppressive or immunodeficient conditions
  • Coagulation disorder contraindicating IM(intramuscular) vaccination
  • Subject has received any licensed vaccine(not including BCG and Hepatitis B)
  • Participation to another study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Confidential

Seoul, South Korea

Location

MeSH Terms

Conditions

Pneumococcal Infections

Condition Hierarchy (Ancestors)

Streptococcal InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfections

Study Officials

  • Confidential Investigator

    Clinical Research Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 16, 2014

First Posted

July 25, 2014

Study Start

September 6, 2014

Primary Completion

October 21, 2016

Study Completion

October 21, 2016

Last Updated

April 20, 2020

Record last verified: 2016-10

Locations

KR(1)